Bilayer Therapeutics
Developing innovative treatments for GI disease and metabolic disorders (obesity & diabetes) based on GLP-1 and TGR5
Developing innovative treatments for GI disease and metabolic disorders (obesity & diabetes) based on GLP-1 and TGR5
Bilayer Therapeutics is a development-stage company focused on pioneering treatments for gastrointestinal (GI) disease and metabolic disorders such as obesity and diabetes. The company's approach utilizes GLP-1 and TGR5 - regulatory mechanisms for metabolism and motility. Founded in 2020 by a team of renowned drug development and delivery experts and gastroenterologists, Bilayer Therapeutics leverages a proprietary bilayer tablet technology to deliver chenodeoxycholate, a naturally occurring bile acid, to achieve its desired effects.
The company's innovative drug candidates, including BL-050 for metabolic disorder and BL-010 for motility disorders such as chronic constipation, aim to address unmet medical needs. Recently, Bilayer Therapeutics secured a $2.00M Venture Round investment on 28 April 2021, with Kendall Capital Partners participating as the investors.
Bilayer Therapeutics operates within the biotechnology, health care, health and wellness, and life sciences industries, with its headquarters based in the United States.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.00M | 1 |
|
28 Apr 2021 |
No recent news or press coverage available for Bilayer Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
